Effect of Empagliflozin on Neutrophil and Lymphocyte Counts, and their Ratio, in Patients with Heart Failure: the EMPEROR Program
Abstract
Heart failure is a condition characterized by fluid buildup (congestion) and inflammation. It affects millions of people worldwide and can lead to symptoms such as shortness of breath and adverse health outcomes. There are two main types of heart failure: • Heart failure with reduced ejection fraction (HFrEF): the heart’s ability to pump blood is weakened. • Heart failure with preserved ejection fraction (HFpEF): the heart’s pumping ability is preserved, but its function is still impaired. Sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, were originally developed to treat type 2 diabetes by promoting the excretion of excess glucose in urine. However, they have also been shown to reduce congestion and systemic inflammation in patients with heart failure, and to improve outcomes in this population. The neutrophil-to-lymphocyte ratio (NLR) reflects the balance between two types of white blood cells: • Neutrophils, which increase in response to inflammation. • Lymphocytes, which may decrease in heart failure, particularly when congestion is severe. A higher NLR may therefore indicate a combination of inflammation and fluid overload. Previous research has shown that patients with heart failure and a high NLR are more likely to experience poorer outcomes, especially those with HFrEF. Data are more limited in HFpEF. Therefore, we propose to analyze two trials that evaluated the effects of SGLT2 inhibitors in patients with HFrEF and HFpEF to explore whether…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.